Current stage -Stage IV Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Read More

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Posted by on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients. Some...

Read More

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of adding sipuleucel-T (Provenge) androgen receptor-targeting agents (ARTAs) such as abiraterone acetate (AA; Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC). The data showed that those receiving both sipuleucel-T and ARTAs were more...

Read More

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jan 30, 2022 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these...

Read More

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Read More

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...

Read More

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Posted by on Jun 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...

Read More

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Searching for patients with advanced prostate cancer to trial an immunotherapy

Searching for patients with advanced prostate cancer to trial an immunotherapy

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...

Read More

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Posted by on Mar 5, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC.  Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2022 Medivizor